Alto Neuroscience (ANRO) News Today $6.19 -0.02 (-0.32%) As of 11:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Alto Neuroscience (NYSE:ANRO) Given Sell (D-) Rating at Weiss RatingsOctober 8 at 4:44 PM | marketbeat.comJohnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term ShareholdersOctober 8 at 9:56 AM | globenewswire.comALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 7 at 6:05 PM | globenewswire.comAlto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Hold" by AnalystsOctober 7 at 2:14 AM | marketbeat.comAlto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia CandidateOctober 6 at 10:45 AM | finance.yahoo.comOptimistic Buy Rating for Alto Neuroscience, Inc. Amidst Promising Developments and FDA Fast Track DesignationOctober 6 at 8:51 AM | tipranks.comResearch Analysts Set Expectations for ANRO FY2025 EarningsOctober 5, 2025 | americanbankingnews.comAlto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia DrugOctober 4, 2025 | msn.comAlto Neuroscience stock soars after FDA grants Fast Track designationOctober 3, 2025 | investing.comAlto Neuroscience granted fast track designation for ALTO-101October 3, 2025 | msn.comJohnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term ShareholdersOctober 3, 2025 | globenewswire.comAlto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with SchizophreniaOctober 3, 2025 | businesswire.comFY2025 Earnings Forecast for ANRO Issued By Chardan CapitalOctober 3, 2025 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Now Covered by Analysts at Chardan CapitalSeptember 30, 2025 | americanbankingnews.comChardan Capital Initiates Coverage of Alto Neuroscience (ANRO) with Buy RecommendationSeptember 29, 2025 | msn.comAlto Neuroscience (NYSE:ANRO) Earns Buy Rating from Analysts at Chardan CapitalSeptember 29, 2025 | marketbeat.comAlto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities LawsuitSeptember 19, 2025 | prnewswire.comInvestors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANROSeptember 19, 2025 | globenewswire.comANRO DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANROSeptember 19, 2025 | globenewswire.comShareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreSeptember 19, 2025 | prnewswire.comANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th DeadlineSeptember 19, 2025 | globenewswire.comFaruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANROSeptember 18, 2025 | prnewswire.comSeptember 19, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ANROSeptember 18, 2025 | globenewswire.comANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 18, 2025 | globenewswire.comAlto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 19, 2025 Deadline to file Lead Plaintiff Motion.September 18, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANROSeptember 18, 2025 | prnewswire.comThe Gross Law Firm Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANROSeptember 18, 2025 | prnewswire.comANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 18, 2025 | prnewswire.comAlto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANROSeptember 18, 2025 | prnewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceSeptember 17, 2025 | globenewswire.comANRO Deadline: ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud LawsuitSeptember 17, 2025 | prnewswire.comANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th DeadlineSeptember 17, 2025 | globenewswire.comANRO LAWSUIT ALERT: Levi & Korsinsky Notifies Alto Neuroscience, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSeptember 16, 2025 | globenewswire.comAlto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANROSeptember 16, 2025 | prnewswire.comANRO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANROSeptember 15, 2025 | globenewswire.comAlto Neuroscience, Inc. Class Action: The Gross Law Firm Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 – ANROSeptember 15, 2025 | globenewswire.comContact The Gross Law Firm by September 19, 2025 Deadline to Join Class Action Against Alto Neuroscience, Inc.(ANRO)September 15, 2025 | prnewswire.comALTO NEUROSCIENCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the FirmSeptember 15, 2025 | globenewswire.comSCS Capital Management LLC Takes $144,000 Position in Alto Neuroscience, Inc. $ANROSeptember 15, 2025 | marketbeat.comAlto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANROSeptember 15, 2025 | prnewswire.comANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 15, 2025 | prnewswire.comANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 14, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANROSeptember 14, 2025 | globenewswire.comAlto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of "Moderate Buy" by AnalystsSeptember 14, 2025 | marketbeat.comANRO Deadline: Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders to Contact the Firm for Information About Their RightsSeptember 13, 2025 | businesswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceSeptember 13, 2025 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANROSeptember 13, 2025 | prnewswire.comANRO Deadline: ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud LawsuitSeptember 12, 2025 | prnewswire.comANRO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANROSeptember 12, 2025 | globenewswire.comShareholders of Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANROSeptember 12, 2025 | prnewswire.com Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANRO Media Mentions By Week ANRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANRO News Sentiment▼0.500.63▲Average Medical News Sentiment ANRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANRO Articles This Week▼167▲ANRO Articles Average Week Get the Latest News and Ratings for ANRO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alto Neuroscience and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Ocugen News Today Larimar Therapeutics News Today Alumis News Today Autolus Therapeutics News Today Astria Therapeutics News Today ADC Therapeutics News Today PureTech Health News Today 4D Molecular Therapeutics News Today Y-mAbs Therapeutics News Today Evolus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANRO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
